Loading the company…
Loading the company…
Families: Coronary intervention (PCI).
All companies · Product and company coverage
In the last ten years FDA made 3 decisions for Advanced Bifurcation Systems (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2023 (1). The latest was on 2023-04-06.
| Family | Decisions on record |
|---|---|
| Coronary intervention (PCI) | 3 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2023-04-06 | PMA | P210014-S002 | Svelte SLENDER® Sirolimus-Eluting Coronary Stent Integrated Delivery System (SLENDER IDS®), Svelte DIRECT Sirolimus-Elut · Postapproval Study Protocol |
| 2022-04-08 | PMA | P210014-S001 | SLENDER Sirolimus-Eluting Coronary Stent Integrated Delivery System(SLENDER IDS®), DIRECT Sirolimus-Eluting Coronary Ste · Postapproval Study Protocol |
| 2021-12-13 | PMA | P210014 | SLENDER Sirolimus-Eluting Coronary Stent Integrated Delivery System and DIRECT Sirolimus-Eluting Coronary Stent Rapid Ex · Coronary drug-eluting stent |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Advanced Bifurcation Systems.